share_log

《大行》高盛對中國醫療健康股投資評級及目標價(表)

Goldman Sachs' investment ratings and Target Price for China's Medical health stocks (table)

AASTOCKS ·  Mar 13 07:43

Goldman Sachs published a research report, listing the latest investment ratings and Target Prices for China's Medical health stocks as follows:

Stock | Investment Rating | Target Price (HKD)

HANSOH PHARMA (03692.HK) | Buy | 20.97 yuan -> 21.51 yuan

SINO BIOPHARM (01177.HK) | Buy | 4.1 yuan -> 3.96 yuan

CSPC PHARMA (01093.HK) | Buy | 8.52 yuan

FOSUN PHARMA (02196.HK) | Neutral | 18.18 yuan -> 16.83 yuan

LIVZON PHARMA (01513.HK) | Neutral | 22.58 yuan -> 21.1 yuan

3SBIO (01530.HK) | Neutral | 8.16 yuan -> 9.02 yuan

UNITED LAB (03933.HK) | Neutral | Target Price 10.25 yuan -> 10.5 yuan

HEPALINK (09989.HK) | Sell | Target Price 3.76 yuan -> 3.47 yuan

SINOPHARM (01099.HK) | Neutral | Target Price 18.97 yuan -> 20.32 yuan

SH PHARMA (02607.HK) | Sell | Target Price 12.87 yuan -> 12.1 yuan

CHINARES PHARMA (03320.HK) | Neutral | Target Price 6.11 yuan -> 6.04 yuan

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 4708

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.